Patents Represented by Attorney, Agent or Law Firm William R. Boudreaux
  • Patent number: 7335799
    Abstract: The present invention relates to novel hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, pancreatitius, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, metabolic syndrome disorders (e.g., Syndrome X), thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient.
    Type: Grant
    Filed: December 23, 2003
    Date of Patent: February 26, 2008
    Assignee: Esperion Therapeutics, Inc.
    Inventors: Jean-Louis Henri Dasseux, Carmen Daniela Oniciu
  • Patent number: 7192940
    Abstract: The present invention relates to novel ether compounds, compositions comprising ether compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising an ether compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.
    Type: Grant
    Filed: July 16, 2004
    Date of Patent: March 20, 2007
    Assignee: Esperion Therapeutics, Inc.
    Inventors: Jean-Louis Henri Dasseux, Carmen Daniela Oniciu
  • Patent number: 7119221
    Abstract: The present invention relates to novel cycloalkyl-hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, Syndrome X, thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient.
    Type: Grant
    Filed: December 23, 2003
    Date of Patent: October 10, 2006
    Assignee: Esperion Therapeutics, Inc.
    Inventors: Jean-Louis Henri Dasseux, Carmen Daniela Oniciu
  • Patent number: 7015232
    Abstract: The present invention is directed to ACE inhibitor-containing compositions stabilized by the presence of magnesium oxide. Preferably, the ACE inhibitor, quinapril, is protected from certain forms of degradation when prepared in a pharmaceutical composition consisting essentially of magnesium oxide as the stabilizing agent. The presence of magnesium oxide also lends itself to favorable processing conditions during the manufacture of ACE inhibitor-containing compositions, especially processing by wet granulation.
    Type: Grant
    Filed: April 22, 2002
    Date of Patent: March 21, 2006
    Assignee: Warner-Lambert Company, LLC
    Inventors: Jane Ellen Daniel, Michael Ray Harris, Gerard Clifford Hokanson, Jay Weiss
  • Patent number: 6828331
    Abstract: What is disclosed are growth hormone secretagogues, and their uses, of the formula wherein R1 is C6H5CH2OCH2—, C6H5 (CH2)3— or indol-3-ylmethyl; Y is pyrrolidin-1-yl, 4-C1-C6 alkylpiperidin-1-yl or NR2R2; R2 are each independently a C1 to C6 alkyl; R3 is 2-napthyl or phenyl para-substituted by W; W is H, F, CF3, C1-C6 alkoxy or phenyl; and R4 is H or CH3, or a pharmaceutically acceptable salt or solvate thereof.
    Type: Grant
    Filed: July 25, 2001
    Date of Patent: December 7, 2004
    Assignee: Eli Lilly and Company
    Inventors: Jeffrey Alan Dodge, Charles Willis Lugar, III
  • Patent number: 6723739
    Abstract: A compound of the formula or a pharmaceutically acceptable salt or solvate thereof. Also provided by the invention are methods of use of the above compounds, and processes for the preparation thereof.
    Type: Grant
    Filed: March 15, 1995
    Date of Patent: April 20, 2004
    Assignee: Eli Lilly and Company
    Inventors: Jeffrey A. Dodge, Charles A. Frolik, Terry D. Lindstrom, Charles W. Lugar, III
  • Patent number: 6639076
    Abstract: This invention relates to novel compounds of formula I wherein A, B, D, E, G, J, L, X, V are as defined in the specification, and the compounds are useful in the modulation of endogenous growth hormone levels in a mammal.
    Type: Grant
    Filed: April 17, 2001
    Date of Patent: October 28, 2003
    Assignee: Eli Lilly and Company
    Inventors: Kenneth Lee Hauser, Jeffrey Alan Dodge, Mark Louis Heiman, Scott Alan Jones, Charles Arthur Alt, Henry Uhlman Bryant, James Densmore Copp, William Harlan Gritton, Charles Willis Lugar, III, Brian Stephen Muehl, Alan David Palkowitz, Andrew Michael Ratz, Gary Anthony Rhodes, Roger Lewis Robey, Timothy Alan Shepherd, Kenneth Jeff Thrasher, William George Trankle
  • Patent number: 6562862
    Abstract: A method of inhibiting a physiological disorder associated with an excess of neuropeptide Y or its symptoms comprising administering to a human in need thereof an effective amount of a compound having the formula wherein R1 and R3 are independently hydrogen,  or  wherein Ar is optionally substituted phenyl; R2 is selected from the group consisting of pyrrolidine, hexamethyleneamino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.
    Type: Grant
    Filed: October 20, 1994
    Date of Patent: May 13, 2003
    Assignee: Eli Lilly and Company
    Inventors: Robert F. Bruns, Jr., Donald R. Gehlert, J. Jeffry Howbert, William H. W. Lunn
  • Patent number: 6545027
    Abstract: A method of modulating NF-kB transcription factor comprising administering to a human in need thereof an effective amount of a compound having the formula wherein R1 and R3 are independently hydrogen,  wherein Ar is optionally substituted phenyl; R2 is selected from the group consisting of pyrrolidine, hexamethyleneamino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: April 8, 2003
    Assignee: Eli Lilly and Company
    Inventors: David T. Berg, David S. Calnek, Brian W. Grinnell
  • Patent number: 6489355
    Abstract: This invention encompasses methods for the inhibition of a physiological disorder associated with amyloidogenic proteins, which method comprises administering to a human in need thereof an effective amount of a compound of Formula I wherein R1 and R3 are independently hydrogen, wherein Ar is optionally substituted phenyl; R2 is selected from the group consisting of pyrrolidine, hexamthylenemino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.
    Type: Grant
    Filed: December 1, 1993
    Date of Patent: December 3, 2002
    Assignee: Eli Lilly and Company
    Inventor: William H. W. Lunn
  • Patent number: 6436958
    Abstract: A method of inhibiting auto immune diseases comprising administering to a human in need thereof an effective amount of a compound having the formula wherein R1 and R3 are independently hydrogen, —CH3, or wherein Ar is optionally substituted phenyl; R2 is selected from the group consisting of pyrrolidine, hexamethyleneamino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.
    Type: Grant
    Filed: May 19, 1995
    Date of Patent: August 20, 2002
    Assignee: Eli Lilly and Company
    Inventor: Steven H. Zuckerman
  • Patent number: 6417198
    Abstract: A method of inhibiting one or more CNS disorders in a post-menopausal woman comprising administering to a female human in need of treatment an effective amount of a compound having the formula wherein R1 and R3 are independently hydrogen, wherein Ar is optionally substituted phenyl; R2 is selected from the group consisting of pyrrolidine, hexamethyleneamino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.
    Type: Grant
    Filed: December 21, 1993
    Date of Patent: July 9, 2002
    Assignee: Eli Lilly and Company
    Inventors: Henry U. Bryant, Andrew L. Glasebrook, Timothy A. Grese, David L. Phillips
  • Patent number: 6403615
    Abstract: This invention provides methods which are useful for the inhibition of the various medical conditions associated with estrogen deprivation syndrome including osteoporosis and hyperlipidemia utilizing compounds of formula I:
    Type: Grant
    Filed: September 29, 2000
    Date of Patent: June 11, 2002
    Assignee: Eli Lilly and Company
    Inventor: George Joseph Cullinan
  • Patent number: 6395769
    Abstract: This invention provides methods which are useful for the inhibition of the various medical conditions associated with estrogen deprivation syndrome including osteoporosis and hyperlipidemia utilizing compounds of formula I:
    Type: Grant
    Filed: May 12, 2000
    Date of Patent: May 28, 2002
    Assignee: Eli Lilly and Company
    Inventor: George Joseph Cullinan
  • Patent number: 6395719
    Abstract: The present invention is directed to increasing levels of acetylcholine by the administration of 2-aryl-3-aroylbenzo[b]thiophenes.
    Type: Grant
    Filed: November 14, 2000
    Date of Patent: May 28, 2002
    Assignee: Eli Lilly and Company
    Inventors: Henry Uhlman Bryant, Michele Annette Glinn, Steven Marc Paul, Xin Wu
  • Patent number: 6353003
    Abstract: The current invention relates to a method for decreasing levels of homocysteine and/or C-reactive protein in humans comprising administering to a mammal in need thereof an effective amount of a compound of formula I: or a pharmaceutical salt or solvate thereof.
    Type: Grant
    Filed: May 3, 1999
    Date of Patent: March 5, 2002
    Assignee: Eli Lilly and Company
    Inventor: Pamela Wang Anderson
  • Patent number: 6329342
    Abstract: The present invention is directed to methods for the modulation of cardiac function which comprise the administration of certain compounds, as defined herein, having growth hormone secretagogue activity.
    Type: Grant
    Filed: February 18, 2000
    Date of Patent: December 11, 2001
    Assignee: Eli Lilly and Company
    Inventors: Raymond F. Kauffman, Alan D. Palkowitz
  • Patent number: 6303634
    Abstract: A method of preventing breast cancer comprising administering for a sufficient term to a human in need thereof an effective amount of a compound having the formula and pharmaceutically acceptable salts and solvates thereof.
    Type: Grant
    Filed: August 5, 1999
    Date of Patent: October 16, 2001
    Assignee: Eli Lilly and Company
    Inventors: Fredric J Cohen, Robert S Eckert, Joan E Glusman, Ronald K Knickerbocker, Nikolaus T Nickelsen, Teri J Scott
  • Patent number: 6288108
    Abstract: The current invention relates to a method for increasing levels of acetylcholine comprising administering to a mammal in need thereof, an effective amount of a compound of formula (I), and optionally an AChE inhibitor.
    Type: Grant
    Filed: November 14, 2000
    Date of Patent: September 11, 2001
    Assignee: Eli Lilly and Company
    Inventors: Henry Uhlman Bryant, Michele Annette Glinn, Steven Marc Paul, Xin Wu
  • Patent number: 6274601
    Abstract: A method of inhibiting ulcerative mucositis comprising administering to a human in need thereof an effective amount of a compound having the formula wherein R1 and R3 are independently hydrogen, wherein Ar is optionally substituted phenyl; R2 is selected from the group consisting of pyrrolidine, hexamethyleneamino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.
    Type: Grant
    Filed: September 22, 1995
    Date of Patent: August 14, 2001
    Assignee: Eli Lilly and Company
    Inventor: George J. Cullinan